Floatz logo

Epirubicin

Advanced Solid Tumor (Phase 1)

Aptabio Therapeutics, Inc.Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

9 Active assets in the Advanced Solid Tumor (Phase 1) cohort.

Asset / SponsorPhaseRating
Nhwd-870
Zhejiang Wenda Pharma Technology LTD.
Phase 2CCC
Imm-6-415
Immuneering Corporation
Phase 1/2CCC
an8025 is a multifunctional antibody fusion protein
Adlai Nortye Biopharma Co., Ltd.
Phase 1CC
Apx-343A
Aptabio Therapeutics, Inc.
Phase 1CC
Pembrolizumab
Aptabio Therapeutics, Inc.
Phase 1CC

View all 9 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →